Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Emergent Product Development Gaithersburg Inc. maintains a portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that the company's current patenting efforts are not confined to a narrow niche but are instead spread across different technical examinations within the biotechnology sector.
The busiest examiner identified in the data is SONG, JIANFENG, who is handling 1 pending office action. Since there are 2 pending office actions in total, the workload is split among the 2 distinct examiners involved. This suggests a diversified prosecution landscape where the company must navigate the specific requirements and interpretations of 2 distinct art units simultaneously. The involvement of different examiners implies that the underlying technologies span different classification areas.
For patent practitioners, the presence of SONG, JIANFENG managing 1 pending office action requires a specific approach to that individual's examination style. The overall strategy must account for the varied perspectives present in the Biotechnology & Pharmaceuticals space. This level of activity reflects a multi-faceted engagement with the patent office, requiring coordination across the active matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SONG, JIANFENG | 1 | 56.4% | +33.0% |
| BOATENG, AFUA BAMFOAA | 1 | 46.7% | +64.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246982 | STABILIZED ALKYL NITRITE COMPOSITIONS | SONG, JIANFENG | 8d overdue |
| 17919574 | OPIOID ANTAGONIST FORMULATIONS | BOATENG, AFUA BAMFOAA | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18246982 | STABILIZED ALKYL NITRITE COMPOSITIONS | SONG, JIANFENG | 1613 | §103 | Non-Final OA | 8d overdue | Pending | Mar 28, 2023 |
| 17919574 | OPIOID ANTAGONIST FORMULATIONS | BOATENG, AFUA BAMFOAA | 1617 | §103 | Non-Final OA | — | Pending | Oct 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEmergent Product Development Gaithersburg Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jianfeng Song has the most, with 1 of Emergent Product Development Gaithersburg Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
